Background: Human organic cationic transporter1 (Hoct1) is a plasma membrane transporter responsible for the main influx of Imatinib into chronic myeloid leukemia (CML) cells. Single nucleotide polymorphisms (SNPs) in...Background: Human organic cationic transporter1 (Hoct1) is a plasma membrane transporter responsible for the main influx of Imatinib into chronic myeloid leukemia (CML) cells. Single nucleotide polymorphisms (SNPs) in the gene coding for hOCT1 are important factors causing Imatinib resistance. We investigated the frequency of hOCT1 SNP C480G among Egyptian CML patients and its relation to early molecular response as an indicator of treatment outcome. Materials and Methods: Two groups of CML patients were included in this study. Group I consisted of 25 patients responding to Imatinib treatment (Imatinib responsive) and group II consisted of 25 patients resistant to Imatinib (Imatinib resistant). Response criteria were assessed according to the NCCN (National Comprehensive Cancer Network) guidelines 2017. Twenty healthy controls of matched age and sex were also included (group III). For all patients, we studied hOCT1 C480G at initial presentation using Taqman drug metabolism genotyping as well as BCR-ABL percent at diagnosis and after 3 months interval. Results: hOCT1 C480G was present in 32% of studied CML patients. CC (wild) was detected in 68% of group I and 64% of group II. CG (mutant heterozygous) was present in 28% of group I and 36% of group II while GG (mutant homozygous) was detected in only one case in group I. CG was also detected in 15% of control subjects There was no significant difference between hOCT1 C480G polymorphism and Early Molecular Response (χ2 = 0.089, p = 0.765). Conclusions: hOCT1 C480G polymorphism has no association with Imatinib resistance in Egyptian population. However, further studies on a larger number of patients are still needed to confirm this finding.展开更多
Platinum(Pt)-based antitumor agents are effective in the treatment of many solid malignancies. However, their efficacy is limited by toxicity and drug resistance. Reduced intracellular Pt accumulation has been consist...Platinum(Pt)-based antitumor agents are effective in the treatment of many solid malignancies. However, their efficacy is limited by toxicity and drug resistance. Reduced intracellular Pt accumulation has been consistently shown to correlate with resistance in tumors. Proteins involved in copper homeostasis have been identified as Pt transporters. In particular, copper transporter receptor 1(CTR1), the major copper influx transporter, has been shown to play a significant role in Pt resistance. Clinical studies demonstrated that expression of CTR1 correlated with intratumoral Pt concentration and outcomes following Pt-based therapy. Other CTRs such as CTR2, ATP7 A and ATP7 B, may also play a role in Pt resistance. Recent clinical studies attempting to modulate CTR1 to overcome Pt resistance may provide novel strategies. This review discusses the role of CTR1 as a potential predictive biomarker of Pt sensitivity and a therapeutic target for overcoming Pt resistance.展开更多
目的探讨人尿酸盐转运基因（hURATl）C／T单核苷酸多态性与高尿酸血症易感性的关系。方法分别检索PubMed、CNKI、VIP、CBM、GoogleScholar、Science Direct Online和万方数据库（1990--2013年）中，有关hURATl C／T单核苷酸多态性与高...目的探讨人尿酸盐转运基因（hURATl）C／T单核苷酸多态性与高尿酸血症易感性的关系。方法分别检索PubMed、CNKI、VIP、CBM、GoogleScholar、Science Direct Online和万方数据库（1990--2013年）中，有关hURATl C／T单核苷酸多态性与高尿酸血症易感性的观察性研究。应用Stata10．0统计学软件对相关研究结果进行异质性 检验和数据合并，并评估发表偏倚。结果有6篇文献的9个研究符合纳入标准。Meta分析结果显示，hURATl基因rs7932775位点的显性模型合并oR为1．470（95％CI=1．023～1．963）、隐性模型合并OR为1．327（95％CI=1．104～1．595）、共显性模型合并OR为1．367（950ACI=1．087～1.718），rs3825016位点则分别为．30695％CI=1．008～1．691）、1．521（95％CI=1．265～1．830）、1．355（95％CI=11182～1．554）。结论hURATl基因rs7932775、rs3825016位点多态性可能与高尿酸血症有关。展开更多
文摘Background: Human organic cationic transporter1 (Hoct1) is a plasma membrane transporter responsible for the main influx of Imatinib into chronic myeloid leukemia (CML) cells. Single nucleotide polymorphisms (SNPs) in the gene coding for hOCT1 are important factors causing Imatinib resistance. We investigated the frequency of hOCT1 SNP C480G among Egyptian CML patients and its relation to early molecular response as an indicator of treatment outcome. Materials and Methods: Two groups of CML patients were included in this study. Group I consisted of 25 patients responding to Imatinib treatment (Imatinib responsive) and group II consisted of 25 patients resistant to Imatinib (Imatinib resistant). Response criteria were assessed according to the NCCN (National Comprehensive Cancer Network) guidelines 2017. Twenty healthy controls of matched age and sex were also included (group III). For all patients, we studied hOCT1 C480G at initial presentation using Taqman drug metabolism genotyping as well as BCR-ABL percent at diagnosis and after 3 months interval. Results: hOCT1 C480G was present in 32% of studied CML patients. CC (wild) was detected in 68% of group I and 64% of group II. CG (mutant heterozygous) was present in 28% of group I and 36% of group II while GG (mutant homozygous) was detected in only one case in group I. CG was also detected in 15% of control subjects There was no significant difference between hOCT1 C480G polymorphism and Early Molecular Response (χ2 = 0.089, p = 0.765). Conclusions: hOCT1 C480G polymorphism has no association with Imatinib resistance in Egyptian population. However, further studies on a larger number of patients are still needed to confirm this finding.
文摘Platinum(Pt)-based antitumor agents are effective in the treatment of many solid malignancies. However, their efficacy is limited by toxicity and drug resistance. Reduced intracellular Pt accumulation has been consistently shown to correlate with resistance in tumors. Proteins involved in copper homeostasis have been identified as Pt transporters. In particular, copper transporter receptor 1(CTR1), the major copper influx transporter, has been shown to play a significant role in Pt resistance. Clinical studies demonstrated that expression of CTR1 correlated with intratumoral Pt concentration and outcomes following Pt-based therapy. Other CTRs such as CTR2, ATP7 A and ATP7 B, may also play a role in Pt resistance. Recent clinical studies attempting to modulate CTR1 to overcome Pt resistance may provide novel strategies. This review discusses the role of CTR1 as a potential predictive biomarker of Pt sensitivity and a therapeutic target for overcoming Pt resistance.
文摘目的探讨人尿酸盐转运基因（hURATl）C／T单核苷酸多态性与高尿酸血症易感性的关系。方法分别检索PubMed、CNKI、VIP、CBM、GoogleScholar、Science Direct Online和万方数据库（1990--2013年）中，有关hURATl C／T单核苷酸多态性与高尿酸血症易感性的观察性研究。应用Stata10．0统计学软件对相关研究结果进行异质性 检验和数据合并，并评估发表偏倚。结果有6篇文献的9个研究符合纳入标准。Meta分析结果显示，hURATl基因rs7932775位点的显性模型合并oR为1．470（95％CI=1．023～1．963）、隐性模型合并OR为1．327（95％CI=1．104～1．595）、共显性模型合并OR为1．367（950ACI=1．087～1.718），rs3825016位点则分别为．30695％CI=1．008～1．691）、1．521（95％CI=1．265～1．830）、1．355（95％CI=11182～1．554）。结论hURATl基因rs7932775、rs3825016位点多态性可能与高尿酸血症有关。
